Cargando…
Retracted: Efficacy Investigation of TACE Combined with Lenvatinib and Sintilimab in Intermediate-Stage Hepatocellular Carcinoma
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Hindawi
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10396735/ https://www.ncbi.nlm.nih.gov/pubmed/37538090 http://dx.doi.org/10.1155/2023/9791613 |
| _version_ | 1785083827910082560 |
|---|---|
| author | Markers, Disease |
| author_facet | Markers, Disease |
| author_sort | Markers, Disease |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10396735 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Hindawi |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-103967352023-08-03 Retracted: Efficacy Investigation of TACE Combined with Lenvatinib and Sintilimab in Intermediate-Stage Hepatocellular Carcinoma Markers, Disease Dis Markers Retraction Hindawi 2023-07-26 /pmc/articles/PMC10396735/ /pubmed/37538090 http://dx.doi.org/10.1155/2023/9791613 Text en Copyright © 2023 Disease Markers. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Retraction Markers, Disease Retracted: Efficacy Investigation of TACE Combined with Lenvatinib and Sintilimab in Intermediate-Stage Hepatocellular Carcinoma |
| title | Retracted: Efficacy Investigation of TACE Combined with Lenvatinib and Sintilimab in Intermediate-Stage Hepatocellular Carcinoma |
| title_full | Retracted: Efficacy Investigation of TACE Combined with Lenvatinib and Sintilimab in Intermediate-Stage Hepatocellular Carcinoma |
| title_fullStr | Retracted: Efficacy Investigation of TACE Combined with Lenvatinib and Sintilimab in Intermediate-Stage Hepatocellular Carcinoma |
| title_full_unstemmed | Retracted: Efficacy Investigation of TACE Combined with Lenvatinib and Sintilimab in Intermediate-Stage Hepatocellular Carcinoma |
| title_short | Retracted: Efficacy Investigation of TACE Combined with Lenvatinib and Sintilimab in Intermediate-Stage Hepatocellular Carcinoma |
| title_sort | retracted: efficacy investigation of tace combined with lenvatinib and sintilimab in intermediate-stage hepatocellular carcinoma |
| topic | Retraction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10396735/ https://www.ncbi.nlm.nih.gov/pubmed/37538090 http://dx.doi.org/10.1155/2023/9791613 |
| work_keys_str_mv | AT markersdisease retractedefficacyinvestigationoftacecombinedwithlenvatinibandsintilimabinintermediatestagehepatocellularcarcinoma |